Merz Pharma Canada Ltd. Commits To Funding A New Fellowship In Spasticity And Tone-Related Impairment For The Next Five Years
TORONTO--(BUSINESS WIRE)--Merz Pharma Canada, Ltd., a division of Merz North America (US affiliate of the global Merz Pharma Group), today announced that it has committed up to $75,000 per year, for the next five years towards a fellowship in spasticity and tone-related impairment offered through the Canadian Association of Physical Medicine & Rehabilitation’s (CAPM&R) Canadian Physiatrists Research and Development Foundation (CPRDF). Merz’s contribution will fund one-year fellowship grants to advance the science and body of knowledge in spasticity management, leading to better outcomes for patients with spasticity.
“At Merz, we believe that one of the most important ways we can help patients with spasticity is to support initiatives that foster medical education and training in the neurorehabilitation and neurology space,“ said Bob Bennett, President and General Manager of Merz Pharma Canada. “By providing funding for this fellowship, we hope to raise awareness of spasticity among the next generation of practicing specialists, ensuring that they are better prepared to diagnose and treat this condition.”
In collaboration with a committee of top academic specialists from across Canada, the Merz Fellowship in Spasticity and Tone Related Impairment was presented on May 26, 2016 in London, Ontario at the CAPM&R Annual Scientific Meeting. The fellowship supports the training of exceptionally qualified physiatrists in preparation for a clinical career in spasticity and movement disorders. Training emphasizes a patient-centric approach and includes hands-on experience in clinics, workshops, and professional meetings. Canadian medical physiatry and neurology residents or practicing specialists may apply for the fellowship, which begins in July 2017.
Spasticity affects men, women, and children of all backgrounds, and an estimated 12 million people suffer from this disorder worldwide. Multiple treatment options exist, but there is currently no cure for spasticity and its symptoms, which cause mild to severe degrees of disability and pain.
About Merz North America
Merz North America is a specialty healthcare company that develops and commercializes innovative, high-quality treatment solutions in aesthetics, dermatology and neurosciences in the U.S. and Canada. Our ambition is to become the most admired, trusted and innovative aesthetics and neurotoxin company. By developing products that improve patients’ health and help them to live better, feel better and look better, we will continue to make significant contributions to the well-being of individuals around the world.
For more information about Merz Pharma Canada, Ltd. or their products, please visit www.merzcanada.com. For information regarding Merz products and operations in the United States, please visit www.merzusa.com.